Sinopharm Capital

Sinopharm Capital

A private equity firm in China that focuses on medical and healthcare, pharmaceuticals, biotechnology, medical devices, healthcare and medical supply, and services for elderly and persons with disability

Edit ID  13592420 

Henry Ogolla
Henry Ogolla approved a suggestion from Golden's AI on 19 Feb, 2020
Edits made to:
Article (+8/-8 characters)
Article

Sinopharm Capital is a private equity firm in China that focuses on medical and healthcare, pharmaceuticals, biotechnology, medical devices, healthcare and medical supply, and services for elderly and persons with disability. Founded 2012 in ShanghaiShanghai, China, it invests in early stage companies. Its portfolio companies include ArteryFlow, Baicare, Synyi, Novena Global Healthcare Group, Suzhou and Science Technology Development, Dingdang Kuaiyao, HealthCare Biotech, Skynor Medical, Virogin Biotech, and GenFleet Therapeutics. As of February 2020, Sinopharm Capital has made 18 investments. Their most recent investment was on December 31, 2019 with ArteryFlow. Sinopharm Capital has raised a single venture fund, Sino-Singapore Healthcare Fund. This fund was announced on June 21, 2019 and raised a total of $150M.

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.